Solid state beta-sensitive surgical probe

• US 5,744,805 A
• Filed: 05/07/1996
• Issued: 04/28/1998
• Est. Priority Date: 05/07/1996
• Status: Expired due to Term

• Current Assignee: University of Michigan
• Original Assignee: University of Michigan
• Inventors: Wahl, Richard L., Raylman, Raymond R.
• Primary Examiner(s): Hannaher, Constantine
• Application Number:
  US08/643,913
• Time in Patent Office: 721 Days
• Field of Search: 250/370.01, 250/370.06, 250/370.07, 128/659, 600/436
• US Class Current: 250/370.01
• CPC Class Codes: A61B 6/425 using detectors specially adapted to be used in the interior of the body
• CPC Class Codes: A61B 6/4258 for detecting non x-ray radiation, e.g. gamma radiation A61B6/037 takes precedence
• CPC Class Codes: G01T 1/161 Applications in the field of nuclear medicine, e.g. in vivo counting apparatus for radiation diagnosis A61B6/00

Abstract

An intraoperative probe system for preferentially detecting beta radiation over gamma radiation emitted from a radiopharmaceutical. In one embodiment, the probe system is a probe having an ion-implanted silicon charged-particle detector for generating an electrical signal in response to received beta particles. In such an embodiment, a preamplifier may be located in close proximity to the detector filters and amplifies the electrical signal. Furthermore, a wire may be used to couple the probe to a processing unit for amplifying and filtering the electrical signal, and a counter may be utilized to analyze the resulting electrical signal to determine the number of beta particles being received by the detector. Alternatively, the wire can be replaced with an infrared or radio transmitter and receiver for wireless operation of the probe.

Claims

1. A method for detecting radiopharmaceuticals within diseased tissue, comprising the steps of:

a) providing;

i) a patient having a region of diseased tissue, ii) a radiopharmaceutical capable of emitting beta particles and gamma radiation, and iii) an ion-implanted silicon detector;

b) administering said radiopharmaceutical to said patient; and

c) using said ion-implanted silicon detector to detect beta particles emitted from said radiopharmaceutical within said region.

2. The method of claim 1, further comprising the step of discriminating a component of an electrical signal produced by said detector when struck by said beta particles and said gamma radiation.

3. The method of claim 2, wherein said component of said electrical signal is produced by said detector when struck by said gamma radiation.

4. The method of claim 1 wherein said radiopharmaceutical is ¹⁸ -labeled-Fluoro-2-Deoxy-D-Glucose.

5. A probe system comprising a probe having an ion-implanted silicon detector, whereby beta particles emitted from a radiopharmaceutical within diseased tissue are detected.

6. The probe system of claim 5, wherein said probe further comprises a means for discriminating a component of an electrical signal produced by said detector when struck by said beta particles and gamma radiation, said means for discriminating coupled to said detector.

7. The probe system of claim 6, wherein said component of said electrical signal is produced by said detector when struck by said gamma radiation.

8. The probe system of claim 7, wherein said probe further comprises:

a) a preamplifier for amplifying said electrical signal, said preamplifier coupled to said detector; and

b) an amplifier for further amplifying said electrical signal, said amplifier coupled between said preamplifier and said means for discriminating.

9. The probe system of claim 8, further comprising a counter for counting the number of received beta particles, said counter coupled to said means for discriminating.

10. The probe system of claim 9, further comprising:

a) a transmitter for transmitting said electrical signal as a transmitted signal, said transmitter coupled to said means for discriminating; and

b) a receiver for receiving said transmitted signal, said receiver coupled to said counter.

11. The probe system of claim 10 wherein said probe further comprises battery.

12. The probe system of claim 10 wherein said transmitter is an optical transmitter, said receiver is an optical receiver and said transmitted signal is an optical signal.

13. The probe system of claim 12 wherein said optical transmitter is an infrared transmitter, said optical receiver is an infrared receiver and said optical signal is an infrared signal.

14. The probe system of claim 10 wherein said transmitter is a radio transmitter, said receiver is a radio receiver and said transmitted signal is a radio signal.

15. A probe comprising i) an ion-implanted silicon detector, whereby beta particles are detected from a radiopharmaceutical emitting both beta particles and gamma radiation within a diseased tissue and ii) a means for discriminating a component of an electrical signal produced by said detector when struck by said beta particles and said gamma radiation, said means for discriminating coupled to said detector.

16. The probe system of claim 15, wherein said component of said electrical signal is produced by said detector when struck by said gamma radiation.

17. The probe of claim 16, further comprising:

a) a preamplifier for amplifying said electrical signal, said preamplifier coupled to said detector; and

b) an amplifier for further amplifying said electrical signal, said amplified coupled between said preamplifier and said means for discriminating.

18. The probe of claim 17, further comprising a counter for counting the number of received beta particles, said counter coupled between said amplifier and said means for discriminating.